Recommends to exclude “cannot confirm prevention”
Also expected to be imported from Korea… It seems to be controversial
The Financial Times (FT) reported on the 28th that German health authorities have recommended a plan to exclude seniors 65 years of age or older from vaccinating the Corona 19 vaccine jointly developed by AstraZeneca and Oxford University. Controversy is expected as the Korean government has also decided to import this vaccine.
Germany’s Robert Koch Institute, which is the Korea Centers for Disease Control and Prevention, said in a statement on the day that “it is not possible to confirm whether the vaccine is effective against the elderly over the age of 65 due to insufficient data currently available.” He added, “The subjects of the AstraZeneca vaccination recommendation are 18-64 years old.”
Earlier in Europe, claims that the AstraZeneca vaccine was less effective in the elderly or that clinical data were lacking continued. On the 26th, the Commissioner of the European Medicines Agency (EMA) said, “The data are insufficient because studies have been conducted on only a small number of people to see if the AstraZeneca vaccine is effective for the elderly.” It may be concluded that we should focus and approve the use.” When the EMA presents its conclusions, the EU Commission applies it to all 27 member states. The results of the EMA approval review will be available as early as the 29th.
AstraZeneca’s Corona 19 vaccine is a virus vector vaccine prepared by putting the surface antigen gene of the Corona 19 virus into a chimpanzee adenovirus template. It is a vaccine that is given twice to adults over 18 years of age and administered once more 4-12 weeks later.
Vaccines can be stored, transported and handled in refrigerated conditions (2-8 degrees Celsius) for at least 6 months. Accordingly, it is an advantage to be able to inoculate within the existing medical delivery system without establishing a separate distribution system. According to the results of a phase 3 interim analysis published by AstraZeneca, the preventive effect is about 70.4% when the two doses are combined.
Reporter Park Sang-yong [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution